243 related articles for article (PubMed ID: 24069311)
1. Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.
Auner HW; Moody AM; Ward TH; Kraus M; Milan E; May P; Chaidos A; Driessen C; Cenci S; Dazzi F; Rahemtulla A; Apperley JF; Karadimitris A; Dillon N
PLoS One; 2013; 8(9):e74415. PubMed ID: 24069311
[TBL] [Abstract][Full Text] [Related]
2. Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells.
Nishimura N; Radwan MO; Amano M; Endo S; Fujii E; Hayashi H; Ueno S; Ueno N; Tatetsu H; Hata H; Okamoto Y; Otsuka M; Mitsuya H; Matsuoka M; Okuno Y
Cancer Sci; 2019 Oct; 110(10):3275-3287. PubMed ID: 31368616
[TBL] [Abstract][Full Text] [Related]
3. Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97.
Parzych K; Chinn TM; Chen Z; Loaiza S; Porsch F; Valbuena GN; Kleijnen MF; Karadimitris A; Gentleman E; Keun HC; Auner HW
Cell Death Dis; 2015 Dec; 6(12):e2031. PubMed ID: 26720340
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase.
Chou TF; Li K; Frankowski KJ; Schoenen FJ; Deshaies RJ
ChemMedChem; 2013 Feb; 8(2):297-312. PubMed ID: 23316025
[TBL] [Abstract][Full Text] [Related]
5. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways.
Chou TF; Brown SJ; Minond D; Nordin BE; Li K; Jones AC; Chase P; Porubsky PR; Stoltz BM; Schoenen FJ; Patricelli MP; Hodder P; Rosen H; Deshaies RJ
Proc Natl Acad Sci U S A; 2011 Mar; 108(12):4834-9. PubMed ID: 21383145
[TBL] [Abstract][Full Text] [Related]
6. The AAA-ATPase p97 facilitates degradation of apolipoprotein B by the ubiquitin-proteasome pathway.
Fisher EA; Lapierre LR; Junkins RD; McLeod RS
J Lipid Res; 2008 Oct; 49(10):2149-60. PubMed ID: 18550891
[TBL] [Abstract][Full Text] [Related]
7. Sequential actions of the AAA-ATPase valosin-containing protein (VCP)/p97 and the proteasome 19 S regulatory particle in sterol-accelerated, endoplasmic reticulum (ER)-associated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Morris LL; Hartman IZ; Jun DJ; Seemann J; DeBose-Boyd RA
J Biol Chem; 2014 Jul; 289(27):19053-66. PubMed ID: 24860107
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of p97-dependent protein degradation by Eeyarestatin I.
Wang Q; Li L; Ye Y
J Biol Chem; 2008 Mar; 283(12):7445-54. PubMed ID: 18199748
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
10. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
11. Development of p97 AAA ATPase inhibitors.
Chou TF; Deshaies RJ
Autophagy; 2011 Sep; 7(9):1091-2. PubMed ID: 21606684
[TBL] [Abstract][Full Text] [Related]
12. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.
Bianchi G; Oliva L; Cascio P; Pengo N; Fontana F; Cerruti F; Orsi A; Pasqualetto E; Mezghrani A; Calbi V; Palladini G; Giuliani N; Anderson KC; Sitia R; Cenci S
Blood; 2009 Mar; 113(13):3040-9. PubMed ID: 19164601
[TBL] [Abstract][Full Text] [Related]
13. Identification of SVIP as an endogenous inhibitor of endoplasmic reticulum-associated degradation.
Ballar P; Zhong Y; Nagahama M; Tagaya M; Shen Y; Fang S
J Biol Chem; 2007 Nov; 282(47):33908-14. PubMed ID: 17872946
[TBL] [Abstract][Full Text] [Related]
14. Mouse Mammary Tumor Virus Signal Peptide Uses a Novel p97-Dependent and Derlin-Independent Retrotranslocation Mechanism To Escape Proteasomal Degradation.
Byun H; Das P; Yu H; Aleman A; Lozano MM; Matouschek A; Dudley JP
mBio; 2017 Mar; 8(2):. PubMed ID: 28351922
[TBL] [Abstract][Full Text] [Related]
15. p97 Inhibitor CB-5083 Blocks ERAD in Trypanosoma brucei.
Garrison P; Bangs JD
Mol Biochem Parasitol; 2020 Sep; 239():111313. PubMed ID: 32735998
[TBL] [Abstract][Full Text] [Related]
16. VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy.
Lan B; Chai S; Wang P; Wang K
Curr Mol Med; 2017; 17(9):608-618. PubMed ID: 29521227
[TBL] [Abstract][Full Text] [Related]
17. The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group.
Wang Q; Shinkre BA; Lee JG; Weniger MA; Liu Y; Chen W; Wiestner A; Trenkle WC; Ye Y
PLoS One; 2010 Nov; 5(11):e15479. PubMed ID: 21124757
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial Surveillance by Cdc48/p97: MAD vs. Membrane Fusion.
Escobar-Henriques M; Anton V
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961852
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
Sha Z; Goldberg AL
Proc Natl Acad Sci U S A; 2020 Sep; 117(35):21588-21597. PubMed ID: 32817432
[TBL] [Abstract][Full Text] [Related]
20. Distinct steps in dislocation of luminal endoplasmic reticulum-associated degradation substrates: roles of endoplamic reticulum-bound p97/Cdc48p and proteasome.
Elkabetz Y; Shapira I; Rabinovich E; Bar-Nun S
J Biol Chem; 2004 Feb; 279(6):3980-9. PubMed ID: 14607830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
